|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-8-21
|
|
pubmed:abstractText |
Impaired GH secretion is a common finding in patients with primary hyperparathyroidism (PHP). Ghrelin displays strong GH-releasing action, mainly at the hypothalamic level.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1365-2265
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
197-201
|
|
pubmed:meshHeading |
pubmed-meshheading:18221398-Acylation,
pubmed-meshheading:18221398-Adenoma,
pubmed-meshheading:18221398-Adult,
pubmed-meshheading:18221398-Aged,
pubmed-meshheading:18221398-Diagnostic Techniques, Endocrine,
pubmed-meshheading:18221398-Female,
pubmed-meshheading:18221398-Ghrelin,
pubmed-meshheading:18221398-Human Growth Hormone,
pubmed-meshheading:18221398-Humans,
pubmed-meshheading:18221398-Hyperparathyroidism, Primary,
pubmed-meshheading:18221398-Injections, Intravenous,
pubmed-meshheading:18221398-Male,
pubmed-meshheading:18221398-Middle Aged,
pubmed-meshheading:18221398-Parathyroid Neoplasms,
pubmed-meshheading:18221398-Secretory Pathway,
pubmed-meshheading:18221398-Sensitivity and Specificity
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Primary hyperparathyroidism is associated with marked impairment of GH response to acylated ghrelin.
|
|
pubmed:affiliation |
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy.
|
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
